Regenerative Medicine for Parkinson’s Disease

• YASUHARA Takao

  Department of Neurological Surgery, Okayama University Graduate School of Medicine

• KAMEDA Masahiro

  Department of Neurological Surgery, Okayama University Graduate School of Medicine

• AGARI Takashi

  Department of Neurological Surgery, Okayama University Graduate School of Medicine

• DATE Isao

  Department of Neurological Surgery, Okayama University Graduate School of Medicine

Abstract

Regenerative medicine for Parkinson’s disease (PD) is expected to develop dramatically with the advancement of biotechnology as represented by induced pluripotent stem cells. Existing therapeutic strategy for PD consists of medication using L-DOPA, surgery such as deep brain stimulation and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestoration is strongly desired by regenerative medicine. This review article describes the historical development of regenerative medicine for PD, with a focus on fetal nigral cell transplantation and glial cell line-derived neurotrophic factor infusion. Subsequently, the current status of regenerative medicine for PD in terms of cell therapy and gene therapy are reviewed. In the end, the future direction to realize regenerative medicine for PD is discussed.

Journal

• Neurologia medico-chirurgica

  Neurologia medico-chirurgica 55 (2), 113-123, 2015

  The Japan Neurosurgical Society

Keywords

• cell therapy
• dopaminergic neuron
• gene therapy
• induced pluripotent stem cells

Details

• CRID: 1390282680033264128
• NII Article ID: 130004922277
• DOI: 10.2176/nmc.ra.2014-0264
• ISSN: 13498029
• ISSN: 04708105
• PubMed: 25746305
• Web Site: https://www.jstage.jst.go.jp/article/nmc/55/2/55_ra.2014-0264/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016059959
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed